These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216 [TBL] [Abstract][Full Text] [Related]
3. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY mBio; 2020 Sep; 11(5):. PubMed ID: 32978311 [TBL] [Abstract][Full Text] [Related]
4. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326 [TBL] [Abstract][Full Text] [Related]
5. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Ripperger TJ; Uhrlaub JL; Watanabe M; Wong R; Castaneda Y; Pizzato HA; Thompson MR; Bradshaw C; Weinkauf CC; Bime C; Erickson HL; Knox K; Bixby B; Parthasarathy S; Chaudhary S; Natt B; Cristan E; El Aini T; Rischard F; Campion J; Chopra M; Insel M; Sam A; Knepler JL; Capaldi AP; Spier CM; Dake MD; Edwards T; Kaplan ME; Scott SJ; Hypes C; Mosier J; Harris DT; LaFleur BJ; Sprissler R; Nikolich-Žugich J; Bhattacharya D Immunity; 2020 Nov; 53(5):925-933.e4. PubMed ID: 33129373 [TBL] [Abstract][Full Text] [Related]
7. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Robbiani DF; Gaebler C; Muecksch F; Lorenzi JCC; Wang Z; Cho A; Agudelo M; Barnes CO; Gazumyan A; Finkin S; Hägglöf T; Oliveira TY; Viant C; Hurley A; Hoffmann HH; Millard KG; Kost RG; Cipolla M; Gordon K; Bianchini F; Chen ST; Ramos V; Patel R; Dizon J; Shimeliovich I; Mendoza P; Hartweger H; Nogueira L; Pack M; Horowitz J; Schmidt F; Weisblum Y; Michailidis E; Ashbrook AW; Waltari E; Pak JE; Huey-Tubman KE; Koranda N; Hoffman PR; West AP; Rice CM; Hatziioannou T; Bjorkman PJ; Bieniasz PD; Caskey M; Nussenzweig MC Nature; 2020 Aug; 584(7821):437-442. PubMed ID: 32555388 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China. Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199 [TBL] [Abstract][Full Text] [Related]
9. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Ni L; Ye F; Cheng ML; Feng Y; Deng YQ; Zhao H; Wei P; Ge J; Gou M; Li X; Sun L; Cao T; Wang P; Zhou C; Zhang R; Liang P; Guo H; Wang X; Qin CF; Chen F; Dong C Immunity; 2020 Jun; 52(6):971-977.e3. PubMed ID: 32413330 [TBL] [Abstract][Full Text] [Related]
10. Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. Ding S; Laumaea A; Benlarbi M; Beaudoin-Bussières G; Gasser R; Medjahed H; Pancera M; Stamatatos L; McGuire AT; Bazin R; Finzi A Viruses; 2020 Oct; 12(11):. PubMed ID: 33114742 [TBL] [Abstract][Full Text] [Related]
11. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513 [TBL] [Abstract][Full Text] [Related]
12. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Iyer AS; Jones FK; Nodoushani A; Kelly M; Becker M; Slater D; Mills R; Teng E; Kamruzzaman M; Garcia-Beltran WF; Astudillo M; Yang D; Miller TE; Oliver E; Fischinger S; Atyeo C; Iafrate AJ; Calderwood SB; Lauer SA; Yu J; Li Z; Feldman J; Hauser BM; Caradonna TM; Branda JA; Turbett SE; LaRocque RC; Mellon G; Barouch DH; Schmidt AG; Azman AS; Alter G; Ryan ET; Harris JB; Charles RC Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033172 [TBL] [Abstract][Full Text] [Related]
13. Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset. Xiang T; Liang B; Fang Y; Lu S; Li S; Wang H; Li H; Yang X; Shen S; Zhu B; Wang B; Wu J; Liu J; Lu M; Yang D; Dittmer U; Trilling M; Deng F; Zheng X Front Immunol; 2021; 12():708523. PubMed ID: 34220870 [TBL] [Abstract][Full Text] [Related]
14. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838 [TBL] [Abstract][Full Text] [Related]
15. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177 [TBL] [Abstract][Full Text] [Related]
17. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019. Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705 [TBL] [Abstract][Full Text] [Related]
18. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713 [No Abstract] [Full Text] [Related]
19. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105 [TBL] [Abstract][Full Text] [Related]
20. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]